Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Alternative email: alastair.lamb@ouh.nhs.uk

Twitter: @LambAlastair

My connections

  • Carlos Caldas Breast Cancer Functional Genomics Group, CRUK Cambridge Institute
  • Nitzan Rosenfeld Non-Invasive Diagnostics Group, CRUK Cambridge Institute
  • Gail Risbridger Prostate Cancer Research Laboratory, Monash University and Peter MacCallum Cancer Centre, Melbourne

Biography

Born in Edinburgh, but growing up and schooled in South Oxfordshire, I did initial medical training at Oxford (Corpus Christi College) and Edinburgh Universities, followed by registrar training as an ACF/ACL in Cambridge from 2007 – 2016. During this time, I did my PhD with Professor David Neal on the molecular genetics of prostate cancer at the CRUK Cambridge Institute. I undertook specialty fellowship training with Associate Professor Declan Murphy at Peter MacCallum Cancer Centre in Melbourne, Australia 2016-2017 before appointment by Professor Freddie Hamdy to an academic consultant post in Oxford.

Alastair Lamb

MA(Oxon) MBChB PhD FRCS(Urol)

Robotic Surgery Fellow and Academic Clinical Lecturer

My research goal is to provide a robust molecular platform for accurate decision-making in early stage prostate cancer.

I have spent my scientific training investigating how individual genes or groups of genes have driven prostate cancer behaviour. My PhD thesis investigated the role of HES6 as a transcriptional driver in castrate resistant prostate cancer – we found that this single gene fundamentally changed the nature of prostate cancer cells. During this time I was funded by the Cambridge Biomedical Research Centre (NIHR) and GlaxoSmithKline, and also by a Raymond and Beverly Sackler Studentship. Since then, I have been employing integrative genomics in prostate cancer risk stratification as well as disease modelling with patient derived xenografts.

I also have an interest in novel molecular imaging techniques such as 68Ga-PSMA PET/CT and their use in disease stratification and selection of patients for surgery.

False False

Recent Publications

5 View 5 more »